Medindia

X

BD Announces Results for Second Fiscal Quarter

Wednesday, April 23, 2008 General News J E 4
Advertisement
FRANKLIN LAKES, N.J., April 23 BD (Becton,Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of$1.747 billion for the second fiscal quarter ended March 31, 2008,representing an increase of 11 percent over the prior year period. Thisquarter's revenue growth rate reflects the favorable impact on all segmentsfrom foreign currency translation, which overall is estimated to account for 5percentage points of the increase in quarterly revenues.

"We are pleased with our strong results, which were once again driven bysolid company-wide revenue growth and disciplined spending controls that morethan offset the headwind we have been facing as a result of increasing rawmaterial costs," said Edward J. Ludwig, Chairman, President and ChiefExecutive Officer. "Accordingly, we are increasing our earnings guidance forthe full year."

Second Quarter and Six-Month Period of Fiscal Year 2008 and 2007 Earnings

Reported diluted earnings per share from continuing operations of $1.09for the second quarter increased by 18 percent over diluted earnings per sharefrom continuing operations of 92 cents for the second fiscal quarter of 2007.For the six-month period ending March 31, 2008, reported diluted earnings pershare from continuing operations were $2.16. For the six-month period endingMarch 31, 2007, reported diluted earnings per share from continuing operationswere $1.44. The following analysis (Table 1) of diluted earnings per sharefrom continuing operations for the six-month periods ended March 31, 2008 and2007 identifies the specified item that affects comparability of resultsbetween periods. As illustrated, diluted earnings per share from continuingoperations of $2.16 for fiscal 2008 increased by 14 percent over comparablefiscal 2007 diluted earnings per share from continuing operations of $1.89,which exclude the specified item.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $922million, representing an increase of 9 percent from the prior year period.For the six-month period ended March 31, 2008, the BD Medical segment reported10 percent revenue growth. Pharmaceutical Systems and Diabetes Care productsled revenue growth in the segment.

In the BD Diagnostics segment, worldwide revenues for the quarter were$531 million, representing an increase of 12 percent from the prior year'squarter. For the six-month period ended March 31, 2008, the BD Diagnosticssegment reported 15 percent revenue growth. Sales of safety-engineereddevices, TriPath products, and molecular testing systems, including GeneOhm,contributed to revenue growth.

In the BD Biosciences segment, worldwide revenues for the quarter were$294 million, representing an increase of 14 percent from the prior year'squarter. For the six-month period ended March 31, 2008, the BD Biosciencessegment reported 16 percent revenue growth. Demand for research instrumentsas well as clinical and research reagents continued to be the primary growthdrivers.

Geographic Results

Second quarter revenues in the U.S. were $784 million, representing anincrease of 4 percent over the prior year period. Revenues outside the U.S.were $963 million, representing an increase of 17 percent over the prior yearperiod, with approximately 10 percentage points of the increase resulting fromthe favorable impact of foreign currency translation.

For the six-month period ended March 31, 2008, revenues in the U.S. were$1.574 billion, representing an increase of 7 percent over the prior yearperiod. Revenues outside of the U.S. were $1.879 billion, representing anincrease of 17 percent over the prior year period, with approximately 10percentage points of the increase resulting from the favorable impact fromforeign currency translation.

Fiscal 2008 Outlook for Full Year

The Company raised its guidance f
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Liver Diseases: A Huge European Health Burden, But...
S
Cord Blood America in Top 20 in Los Angeles Area B...